Literature DB >> 33765186

Does cystic fibrosis make susceptible to celiac disease?

Nagehan Emiralioglu1, Dilber Ademhan Tural2, Hayriye Hizarcioglu Gulsen3, Yasin Maruf Ergen3, Beste Ozsezen2, Birce Sunman2, İncinur Saltık Temizel3, Ebru Yalcin2, Deniz Dogru2, Uğur Ozcelik2, Nural Kiper2.   

Abstract

Patients with cystic fibrosis (CF) have a higher incidence of celiac disease (CD) than the healthy population; however, the actual incidence of coexisting CF and CD is unclear. In this report, we aimed to evaluate the frequency of CD and CF coexistence and to assess the clinical findings of affected patients during follow-up. We conducted a retrospective review of patients with CF to reveal the frequency of CD and also investigated the clinical characteristics and clinical response to gluten-free diet in patients with CD. The incidence of CD in 515 patients with CF was 1.4%. The median age at the time of CF diagnosis was 2 months (1-6 months). CD was diagnosed in six patients with poor weight gain, fatty stools, and low z score for BMI and one patient with poor weight gain despite a high protein and calorie diet and pancreatic enzyme replacement. The median age of CD diagnosis was 8 years (2-12 years). Except for one patient who was recently diagnosed, the other six patients gained weight and their accompanying symptoms resolved after starting a gluten-free diet.
Conclusion: CD should be investigated in patients with CF in the presence of inadequate weight and/or height gain or poor control of malabsorption symptoms despite appropriate and adequate nutritional and enzyme replacement treatment. What is Known: • CFTR dysfunction may be a risk factor for CD, due to increased intestinal permeability and intestinal inflammation, pancreatic exocrine insufficiency that results in higher antigen load and increased antibodies against to nutritional antigens such as anti-gliadin IgA antibodies. • Although coexistence of CF and CD are rare in the same patient; there is still no consensus on when children with CF should be screened for CD. What is New: • Physicians should consider the investigation of CD in patients with CF, in the presence of inadequate weight and/or height gain or poor control of malabsorption symptoms despite appropriate and adequate nutritional and enzyme replacement treatment. • CFTR dysfunction has been emphasized to develop susceptibility to CD, and patients with CF who have persistent gastrointestinal symptoms despite appropriate and adequate nutritional and enzyme replacement treatment should be screened for CD.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  CFTR dysfunction; Celiac disease; Cystic fibrosis; Malnutrition

Year:  2021        PMID: 33765186     DOI: 10.1007/s00431-021-04011-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  Cystic fibrosis is a risk factor for celiac disease.

Authors:  Jarosław Walkowiak; Anna Blask-Osipa; Aleksandra Lisowska; Beata Oralewska; Andrzej Pogorzelski; Wojciech Cichy; Ewa Sapiejka; Mirosława Kowalska; Michał Korzon; Anna Szaflarska-Popławska
Journal:  Acta Biochim Pol       Date:  2010-03-20       Impact factor: 2.149

Review 2.  Liver involvement in celiac disease.

Authors:  A Rubio-Tapia; J A Murray
Journal:  Minerva Med       Date:  2008-12       Impact factor: 4.806

3.  [Celiac disease and cystic fibrosis: casual association?].

Authors:  G Chiaravalloti; A Baracchini; V Rossomando; C Ughi; M Ceccarelli
Journal:  Minerva Pediatr       Date:  1995 Jan-Feb       Impact factor: 1.312

  3 in total
  3 in total

Review 1.  Pancreatic involvement in celiac disease.

Authors:  Daniel Vasile Balaban; Iulia Enache; Marina Ciochina; Alina Popp; Mariana Jinga
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

Review 2.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

3.  Treatment of cystic fibrosis related bone disease.

Authors:  Jagdeesh Ullal; Katherine Kutney; Kristen M Williams; David R Weber
Journal:  J Clin Transl Endocrinol       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.